SKI-II HCl

Description: SKI-II HCl is a substrate competitive, reversible, and highly specific inhibitor of sphingosine kinase. Sphingosine kinases (Sphk) 1 and 2 play tumour-promoting roles in different cancer types including HCC and thus represent promising pharmacological targets. Co-administration of 5-FU and SKI-II at low sub-toxic concentrations of 20 uM and 5 uM, respectively, synergistically inhibit cell proliferation, markedly reduce cell migration and the clonogenic survival, and increase apoptosis induction in HepG2 cells. Additional Western blot analyses have shown that possible mechanisms underlying enhanced sensitivity to 5-FU induced by dual Sphk 1/2 inhibition could include abrogation of FAK-regulated IGF-1R activity and down-regulation of osteopontin expression culminating in the inhibition of NF-kappaB activity and its downstream signalling mediated by sirtuin 1 and p38 MAPK. Pharmacological blockade of both Sphk isoforms represents a promising strategy to boost the anti-tumour efficacy of 5-FU and provide a rationale for further in vivo studies into the possible use of SKI-II inhibitor as an adjunct to 5-FU treatment in HCC.

References: Biochem Biophys Res Commun. 2017 Jun 10; 487(4):782-788.

Related CAS No: 312636-16-1 (free base)